|
|
|
|
 |
|
|
|
|
|
|
John D. Clemens, M.D.
Director-General
|
|
John D. Clemens,
M.D., Dr. John D. Clemens, Director General of the International Vaccine Institute (IVI), is an international expert on the evaluation of vaccines in developing countries. A graduate of Stanford (B.S.) and Yale (M.D.) Universities, Dr. Clemens is U.S.-Board Certified in Internal Medicine, and received his post-doctoral research training in clinical epidemiology at Yale. From 1983-88, he served as a research scientist at the International Centre for Diarrhoeal Disease Research, Bangladesh, where he led the first efficacy trial of an oral vaccine against cholera, and where he conducted additional research on measles vaccine. After returning to the U.S., he served as Chief of the Epidemiology Section of the Center for Vaccine Development of the University of Maryland, and then as Chief of the Epidemiology Branch of the National Institute of Child Health and Human Development , U.S. National Institutes of Health (NIH). While at NIH he was the Director of the first WHO Collaborating Centre for Vaccine Evaluation in Developing Countries and was a recipient of the NIH Director's Award for Outstanding Research on Vaccine Evaluation. In 1999 he became the first Director-General of the IVI, a position which he continues to hold. Dr. Clemens serves as an Adjunct Professor at the Seoul National University School of Public health.
In addition to field evaluations of vaccines, Dr Clemens' research has focused on innovative methodological approaches to evaluating vaccines in developing country populations, and to generating evidence needed for policy decisions about vaccine introduction in developing countries. He has conducted clinical studies of vaccines against cholera, enterotoxigenic Escherichia coli, typhoid fever, pneumococcus, tuberculosis, Haemophilus influenzae type b, measles, and Japanese encephalitis. His work in the developing world has included studies in Bangladesh, Chile, China, Egypt, India, Indonesia, Mozambique, Pakistan, Thailand, and Vietnam. He has published over 250 original, peer-reviewed articles, and serves on the editorial boards of several international journals. He is an elected member of the American Epidemiology Society and a Fellow of the American College of Epidemiology and of the Infectious Disease Society of America. Over the past 15 years he has served on several WHO Steering Committees, including committees for enteric vaccines, vaccine epidemiology, and vaccine safety, and he currently serves as a member of the Advisory Committee to the Director of the Initiative for Vaccine Research. He currently serves on the Board of the GAVI Alliance.
e-mail : jclemens@ivi.int |
|
|
|
|
|
|
|
|
Michael Goon, MM
Deputy Director-General for Finance & Administration
|
|
Michael F. L. Goon,
joined the Institute in January 2001 as its Deputy Director-General for Administration and Finance. He obtained a Masters in Management (MM) degree from the Asian Institute of Management Philippines. He is a Malaysian national, a Penang State Scholar at the University of Malaysia and a Fellow of the Institute of Directors, UK. Mr. Goon brings with him extensive management experience in both multinational profit organizations and international non-profit organizations. He has held very senior managerial positions in the corporate sector and has brought this vast commercial experience to help improve the organizational practices of the international non-profit world. Mr. Goon has worked in several countries in Malaysia, Singapore, the United Arab Emirates, Bangladesh, India, Philippines and the Ivory Coast. Mr. Goon had a highly successful track record in the corporate world. He grew in his career as a Cost Accountant rising to Chief Financial Accountant, Group Systems Manager, Deputy General Manager and then General Manager of large national and multi-national organizations. With the experiences acquired in the corporate sector, Mr. Goon embarked on a career in non-profit organizations to help build up and strengthen administrative, financial management and governance practices of international non-profit organizations to eventually become centers of excellence. He had worked at the International Center for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) as its Associate Director for Administration and Finance, then joined the agricultural research centers in the Consultative Group for International Agricultural Research (CGIAR) and held positions of Assistant Director General for Administration and Finance at the International Crops Research Institute for Semi-Arid Tropics (ICRISAT), India; Deputy Director General Administration and Finance for the International Rice Research Institute (IRRI), Philippines; and Deputy Director General for Administration and Finance for the West Africa Rice Development Association (WARDA), Ivory Coast, West Africa .
e-mail : mgoon@ivi.int |
|
|
|
|
|
|
|
|
Cecil Czerkinsky, Ph.D.
Deputy Director-General
for Laboratory Sciences
|
|
Dr. Cecil Czerkinsky,
a French immunologist, joined the International Vaccine
Institute as the Deputy Director-General for Laboratory
Sciences in October 2005.
Before joining the IVI, Dr. Czerkinsky has been serving
as the Director of the Division of Mucosal Immunology
and Vaccinology at INSERM (French National Institute
of Health and Medical Research) since 1997, focusing
on vaccine research and discovery of the basic mechanisms
governing induction of immunity in mucosal organs.
Dr. Czerkinsky received doctoral degrees from the University
of Lyon Odontology Faculty in France, and the University
of Gothenburg in Sweden where he served as a professor
of the immunology. He has more than 130 scientific peer-reviewed
publications in immunology and vaccinology.
Dr. Czerkinsky invented the ELISPOT, a method for monitoring
immune responses in humans and animals, which is used
in laboratories world-wide. His work has been focused
on basic immunological mechanisms pertaining to vaccine
development against infections, auto-immune disorders
and allergies. Dr. Czerkinsky holds several patents
in these areas.
He is a co-founder of several biotechnology companies,
including Maxim Pharmaceuticals Inc., a U.S. biopharmaceutical
firm devoted to the development of therapeutic drugs
for cancer and liver diseases.
e-mail : cczerkinsky@ivi.int
|
|
|
|
|
|
|
|
|
Harold Margolis, M.D.
Deputy Director-General of IVI for PDVI Program
|
|
Harold Margolis, M.D. Harold S. Margolis, MD, is Director of the Pediatric Dengue Vaccine Initiative, a program of the International Vaccine Institute. He recently retired from the Centers for Disease Control and Prevention where he became an Epidemic Intelligence Service (EIS) Officer in 1975. At CDC, he directed viral hepatitis research and prevention activities from 1987 to 2004, and was Director of a World Health Organization Collaborating Center for Research and Reference in Viral Hepatitis. During 2001-2002 he was CDC's Senior Advisor for Smallpox Preparedness and Response.
Dr. Margolis is a pediatrician and a fellow of the American Academy of Pediatrics. His research and public health interests have focused on evaluation and introduction of new vaccines, molecular epidemiology, and the development of evidenced-based public health policy. He is the author or co-author of over180 peer reviewed publications.
e-mail : hsmargolis@ivi.int |
|
|
|
|
|
|
|
|
.jpg)
Michael Favorov, M.D., Ph.D., D.Sc.
Deputy Director-General for Translational Research
|
|
Michael Favorov, M.D., Ph.D., D.Sc. is a medical epidemiologist with more than 30 years of experience in a wide range of activities focusing on infectious diseases, including field surveillance studies, discovery of viruses, developing new assays (for which he holds four patents), and leading efforts with groups of countries to develop regional approaches to disease prevention. Dr. Favorov has two doctoral degrees in infectious disease, studied hepatitis non A, non B, and later contributed significantly to the discovery of hepatitis E virus (HEV). As a epidemiologist in several countries of Asia, he headed investigations of outbreaks of viral hepatitis (A, B, C, D, E); developed improved treatment and case management for pregnant women infected with HEV; conducted trials of hepatitis A and hepatitis B vaccines; and served as director of the USSR national viral hepatitis reference laboratory, a WHO collaborative Center. From 1991 to 2008, he worked for the U.S. Centers for Disease Control and Prevention, including eight years as Director of the Central Asia Regional Office. His major accomplishments at the CDC include: developing diagnostic tests and diseases specific surveillance for various types of hepatitis (A, B, C, D, E); playing a key role in developing policy, regulatory guidelines, and government committees for the implementation of universal hepatitis B immunization, malaria control, and interventions to reduce infant mortality; establishing infectious disease surveillance systems in several countries of Asia, including national routine case-based tuberculosis electronic surveillance; conducting numerous disease outbreak investigations and control activities; organizing training programs in emerging infectious disease surveillance and response; and leading a non-inferiority study of hepatitis A vaccine for HAV infection post-exposure prophylaxis. Dr. Favorov was responsible for a 16-fold increase in the CDC regional office budget over a seven-year period.
e-mail : mfavorov@ivi.int |
|
|
|
|
